Table 1.

Cytotoxicity of the EGFR tyrosine kinase inhibitor tyrphostin B46 or the EGFR-targeted recombinant toxins TGF-α-ETA and scFv(14E1)-ETA toward neuroblastoma cells

Cell lineIC50 (ng/mL), mean ± SD
IC50 (μmol/L), mean ± SD
CisplatinTGF-α-ETAscFv(14E1)-ETATyrphostin B46*
UKF-NB-376.6 ± 37.3192.9 ± 31.1745.1 ± 221.97,7 ± 1,9
UKF-NB-3rCDDP10001,489.6 ± 262.614.7 ± 9.4155.9 ± 41.211,5 ± 0,8
IMR-3237.0 ± 17.783.9 ± 5.052.8 ± 10.55.4 ± 0.8
IMR-32rCDDP10002,800.7 ± 136.344.8 ± 8.625.0 ± 7.310.0 ± 0.9
NLF141.5 ± 27.925.0 ± 4.551.1 ± 7.19.5 ± 3.0
NLFrCDDP10002,269.1 ± 959.97.1 ± 3.214.6 ± 1.932,9 ± 5.2
SH-SY5Y121.4 ± 54.3192.7 ± 35.7987.9 ± 21.011,6 ± 1.6
SH-SY5YrCDDP500558.2 ± 65.120.89 ± 3.54105.6 ± 20.0021.0 ± 4.1
  • * IC50 for EGFR tyrosine kinase inhibition = 0.7 μmol/L.